Malpani, Rohit Archives - Oxfam Policy & Practice

Briefing paper

Eye on the Ball: Medicine regulation – not IP enforcement – can best deliver quality medicine

02/02/2011

6 documents

51 pages long

Languages: English, French, Spanish

Keywords

Overview

Poor-quality medicines pose a serious threat to patients and public health in developing countries. The World Health Organisation estimates nearly one-third of all countries lack adequate drug-regulatory capacity to monitor medicines safety. Under the guise of addressing this problem, some rich countries are pushing for new intellectual-property rules and a reliance on police action to […]

View resource

Briefing paper

Trading Away Access to Medicines: How the European Union’s trade agenda has taken a wrong turn

20/10/2009

7 documents

32 pages long

Languages: English, French, Spanish, Thai

Keywords

Overview

Access to medicines poses a critical challenge in developing countries, largely because prices are high, and new or adapted medicines and vaccine to address diseases of the developing world are lacking. ore than 5 million people in low and middle income countries still lack access to the anti-retroviral medicines needed to treat HIV and AIDS. […]

View resource

Briefing paper

Ending the R&D Crisis in Public Health: Promoting pro-poor medical innovation

13/11/2008

6 documents

50 pages long

Languages: English, French, German, Spanish

Keywords

Access to medicines

Overview

Diseases that disproportionately affect the developing world cause immense suffering and ill health. Medical innovation has the potential to deliver new medicines, vaccines, and diagnostics to overcome these diseases, yet few treatments have emerged. Current efforts to resolve the crisis are inadequate: financing for research and development (R&D) is insufficient, uncoordinated, and mostly tied to […]

View resource

Briefing paper

Investing For Life: Meeting poor people’s needs for access to medicines through responsible business practices

27/11/2007

3 documents

57 pages long

Languages: English, French, Spanish

Keywords

Overview

There are major shortcomings in the pharmaceutical industry’s current initiatives to ensure that poor people have access to medicines. To shore up its own flagging economic performance, the industry is increasingly looking to the potentially huge markets within emerging economies. Yet, poor people who live in these countries still desperately lack affordable and appropriate medicines. […]

View resource

Briefing paper

All Costs, No Benefits: How TRIPS plus intellectual property rules in the US-Jordan FTA affect access to medicines

21/03/2007

4 documents

37 pages long

Languages: Arabic, English, French, Spanish

Keywords

Overview

The USA continues to impose TRIPS-plus rules on developing countries, thus preventing poor people from accessing inexpensive, generic medicines. Jordan was required under the terms of its WTO accession package and its free trade agreement (FTA) with the USA to introduce TRIPS-plus rules. Medicine prices have increased drastically, and TRIPS-plus rules were partly responsible for […]

View resource

Briefing paper

Patents Versus Patients: Five years after the Doha Declaration

14/11/2006

8 documents

Languages: Arabic, English, French, German, Spanish

Keywords

Overview

Five years ago, members of the World Trade Organisation (WTO) signed a ministerial agreement to ensure that intellectual property rules would no longer obstruct developing countries’ efforts to protect public health. Since then, however, little has changed. Patented medicines continue to be priced out of reach for the world’s poorest people. Trade rules remain a […]

View resource

Malpani, Rohit

Filter Resources by

Eye on the Ball: Medicine regulation – not IP enforcement – can best deliver quality medicine

Trading Away Access to Medicines: How the European Union’s trade agenda has taken a wrong turn

Ending the R&D Crisis in Public Health: Promoting pro-poor medical innovation

Investing For Life: Meeting poor people’s needs for access to medicines through responsible business practices

All Costs, No Benefits: How TRIPS plus intellectual property rules in the US-Jordan FTA affect access to medicines

Patents Versus Patients: Five years after the Doha Declaration